Cesca is a leading regenerative medicine company that develops, commercializes and markets a range of automated technologies for cell-based therapeutics.
Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology.
Cesca is also leveraging its proprietary AutoXpress® technology platform to develop an automated, functionally-closed CAR-TXpress platform that addresses cellular manufacturing needs in the immuno-oncology field.
January 23, 2017
RegMed Investors’ (RMi) closing bell analysis, why isn’t the sector moving up?
January 20, 2017
RegMed Investors’ (RMi) closing bell analysis, a new tide of shareholder populism is about to kick-off
January 19, 2017
RegMed Investors’ (RMi) closing bell analysis, value keeps slippin’ and sliding from the sector
January 18, 2017
RegMed Investors’ (RMi) closing bell analysis, short-term oversold conditions continue to challenge the sector
January 17, 2017
RegMed Investors’ (RMi) closing bell analysis, investors should reflect about what to do next
January 10, 2017
Low to mixed open expected; RegMed Investors’ (RMi) pre-open, looking for clues of pricing sustainability
January 5, 2017
RegMed Investors’ (RMi) closing bell analysis, weakness ripped the upside a new one
January 5, 2017
Cesca Therapeutics receives (KOOL) FDA approval for significant revisions to its pivotal study?
January 5, 2017
Lower open expected; RegMed Investors’ (RMi) pre-open, JPMorgan's annual health-care conference is about to start in San Francisco
January 4, 2017
RegMed Investors’ (RMi) closing bell analysis: how long has upside pricing been sustainable?
35 companies, 1 interpreter!
Insight, foresight and recommendation
Cesca Therapeutics (KOOL) – January '18 opened at $3.10 and it's beed downhill until February at $2.75 with some upside to $2.95 on 2/16. NOT a believer ...
sellMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.